Clinical trial for effectiveness and safety of WT1 peptide-pulsed allogeneic dendritic cell therapy for childhood patients with chemotherapy-resistant leukemia.
Phase 1
- Conditions
- pediatric leukemia
- Registration Number
- JPRN-UMIN000002105
- Lead Sponsor
- Department of Pediatrics, Shinshu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patient with refractory GVHD. 2.Patient with active infections. 3.Patient wit thrombotic microangiopathy. 4.Patient with hepatic vein thrombosis. 5.Patient with early relapse. 6.Patient with mental, or familial, or geographycal obstacles to perform the trial. 7.Patient who is judged by the physician as not to be appropriate for the therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint of this clinical trial is to evaluate the toxicities and adverse events of the therapy.
- Secondary Outcome Measures
Name Time Method